EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Safety of Remimazolam in Vulnerable Populations

Jia-Yi Ge, Bo-Ran Deng iD, Xiao-Hua Cao, Xing-Jun Liu

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s536873 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Jia-Yi Ge und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, People's Republic of China. Hauptthemen laut MEDLINE: Vulnerable Populations, Benzodiazepines, Hypnotics and Sedatives. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vulnerable populations require careful consideration in drug selection due to their unique physiological conditions. Remimazolam, an innovative ultra-short-acting benzodiazepine, presents several advantages, including rapid onset, brief duration of action, and high predictability. Despite the extensive literature on remimazolam, few studies have specifically evaluated its safety in vulnerable patient populations. This review offers a comprehensive analysis of the safety profile of remimazolam in vulnerable populations, including cardiovascular diseases, neurological disorders, hepatic and renal dysfunction, respiratory conditions, metabolic disorders, rare diseases, and special groups such as the elderly and pediatric patients. It assesses recovery outcomes, hemodynamic stability, and adverse events such as respiratory depression and delirium. In our view, the prophylactic potential of remimazolam in these aspects may not be inferior to traditional anesthetic drugs (propofol, sevoflurane, etomidate, etc). and shows a trend of surpassing them in some aspects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vulnerable PopulationsBenzodiazepinesHypnotics and SedativesHumans

Stichwörter der Autor:innen

deliriumhemodynamic stabilityrecovery outcomesrespiratory depression

Substanzen

remimazolamBenzodiazepinesHypnotics and Sedatives

Autor:innen und Institutionen

  • School of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, People's Republic of China.

ORCID-Profile: Bo-Ran Deng

Zitieren

APA

Ge, J. Y., Deng, B. R., Cao, X. H., & Liu, X. J. (2025). Safety of Remimazolam in Vulnerable Populations. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s536873

Vancouver

Ge JY, Deng BR, Cao XH, Liu XJ. Safety of Remimazolam in Vulnerable Populations. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s536873

BibTeX
@article{Ge2025,
  author = {Ge, Jia-Yi and Deng, Bo-Ran and Cao, Xiao-Hua and Liu, Xing-Jun},
  title = {Safety of Remimazolam in Vulnerable Populations},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s536873}
}
Kostenlos starten →